Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
TARS

TARS - Tarsus Pharmaceuticals Inc Stock Price, Fair Value and News

30.28USD-2.86 (-8.63%)Delayed as of 14 Jun 2024, 11:59 am ET

Market Summary

TARS
USD30.28-2.86
Delayedas of 14 Jun 2024, 11:59 am
-8.63%

TARS Alerts

  • Big jump in Revenue (Y/Y)
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

TARS Stock Price

View Fullscreen

TARS RSI Chart

TARS Valuation

Market Cap

1.3B

Price/Earnings (Trailing)

-8.45

Price/Sales (Trailing)

27.79

EV/EBITDA

-8.27

Price/Free Cashflow

-9.3

TARS Price/Sales (Trailing)

TARS Profitability

EBT Margin

-301.58%

Return on Equity

-53.85%

Return on Assets

-42.43%

Free Cashflow Yield

-10.75%

TARS Fundamentals

TARS Revenue

Revenue (TTM)

45.1M

Rev. Growth (Yr)

1.0K%

Rev. Growth (Qtr)

111.18%

TARS Earnings

Earnings (TTM)

-148.2M

Earnings Growth (Yr)

-52.57%

Earnings Growth (Qtr)

14.73%

Breaking Down TARS Revenue

52 Week Range

14.6132.97
(Low)(High)

Last 7 days

2.6%

Last 30 days

-12.8%

Last 90 days

4.9%

Trailing 12 Months

78.2%

How does TARS drawdown profile look like?

TARS Financial Health

Current Ratio

8.01

Debt/Equity

0.11

Debt/Cashflow

-4.45

TARS Investor Care

Shares Dilution (1Y)

40.96%

Diluted EPS (TTM)

-4.74

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202445.1M000
202327.8M014.4M27.4M
202249.2M41.4M33.6M25.8M
202100057.0M

Tracking the Latest Insider Buys and Sells of Tarsus Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 18, 2024
wahl bryan
sold
-135,742
30.6
-4,436
general counsel
Mar 18, 2024
azamian bobak r.
sold
-318,699
30.6
-10,415
president/ceo and board chair
Mar 18, 2024
mottiwala aziz
sold
-145,840
30.6
-4,766
chief commercial officer
Mar 18, 2024
neervannan seshadri
sold
-149,297
30.6
-4,879
chief operating officer
Mar 18, 2024
whitfield dianne c.
sold
-132,008
30.6
-4,314
chief human resources officer
Mar 15, 2024
wahl bryan
acquired
-
-
12,038
general counsel
Mar 15, 2024
azamian bobak r.
acquired
-
-
28,274
president/ceo and board chair
Mar 15, 2024
mottiwala aziz
acquired
-
-
12,938
chief commercial officer
Mar 15, 2024
whitfield dianne c.
acquired
-
-
11,711
chief human resources officer
Mar 15, 2024
neervannan seshadri
acquired
-
-
13,245
chief operating officer

1–10 of 50

Which funds bought or sold TARS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 21, 2024
China Universal Asset Management Co., Ltd.
added
71.37
160,710
238,710
0.03%
May 17, 2024
Ikarian Capital, LLC
added
36.98
15,318,600
25,818,600
2.83%
May 16, 2024
COMERICA BANK
sold off
-100
-1,154
-
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-5.55
332,216
809,914
-%
May 16, 2024
JANE STREET GROUP, LLC
added
99.81
1,003,390
1,391,300
-%
May 15, 2024
Ghost Tree Capital, LLC
unchanged
-
4,830,000
10,905,000
3.02%
May 15, 2024
TFG Asset Management GP Ltd
reduced
-43.75
157,500
16,357,500
3.70%
May 15, 2024
TWO SIGMA INVESTMENTS, LP
added
105
3,916,690
5,373,480
0.01%
May 15, 2024
Cubist Systematic Strategies, LLC
added
942
1,302,410
1,375,960
0.01%
May 15, 2024
PERCEPTIVE ADVISORS LLC
unchanged
-
20,872,300
47,124,700
0.82%

1–10 of 45

Are Funds Buying or Selling TARS?

Are funds buying TARS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own TARS
No. of Funds

Unveiling Tarsus Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
cormorant asset management, lp
4.83%
1,600,000
SC 13G/A
Feb 14, 2024
rtw investments, lp
9.5%
3,152,341
SC 13G/A
Feb 14, 2024
tang capital partners lp
6.7%
2,204,797
SC 13G/A
Feb 13, 2024
vivo capital ix, llc
2.7%
894,826
SC 13G/A
Feb 09, 2024
morgan stanley
5.9%
1,943,705
SC 13G
Feb 02, 2024
cowen financial products llc
5.77%
1,911,399
SC 13G/A
Feb 02, 2024
timessquare capital management, llc
0%
0
SC 13G/A
Jan 26, 2024
blackrock inc.
7.6%
2,515,124
SC 13G
Jan 22, 2024
paradigm biocapital advisors lp
5.8%
1,927,506
SC 13G
May 05, 2023
cowen financial products llc
5.22%
1,398,983
SC 13G

Recent SEC filings of Tarsus Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
May 08, 2024
10-Q
Quarterly Report
May 08, 2024
8-K
Current Report
Apr 26, 2024
ARS
ARS
Apr 26, 2024
DEF 14A
DEF 14A
Apr 26, 2024
DEFA14A
DEFA14A
Apr 23, 2024
8-K
Current Report
Apr 11, 2024
144
Notice of Insider Sale Intent
Mar 28, 2024
144
Notice of Insider Sale Intent
Mar 19, 2024
4
Insider Trading
Mar 19, 2024
4
Insider Trading

Peers (Alternatives to Tarsus Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
55.6B
6.8B
13.11% 15.14%
-9.32
8.12
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.2B
2.0B
8.19% -19.39%
-60.96
10.11
75.20% 68.82%
16.0B
2.5B
5.74% -10.79%
77.85
6.47
13.74% 186.89%
14.1B
3.8B
9.90% 2.05%
18.88
3.74
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.17% 71.70%
-9.93
48.09
54.84% -28.31%
5.2B
524.1M
3.28% -53.81%
-12.38
9.86
394.93% 39.61%
3.4B
251.0M
-6.27% -10.41%
-11.62
13.72
73.58% -86.73%
3.3B
240.7M
15.67% -25.01%
-6.96
12.77
-1.03% -213.92%
2.5B
813.8M
1.62% -37.45%
-1.5K
3.06
56.43% 98.83%
2.1B
996.6M
11.65% 94.95%
-5.3
2.12
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-7.16% 29.42%
27.77
4.4
60.38% -34.49%
564.4M
881.7K
22.84% 567.64%
-16.72
481.06
-77.61% 33.36%
244.6M
4.2M
-17.34% 57.33%
-1.96
58.8
-66.30% 48.24%
22.1M
2.1M
36.17% 271.01%
-0.95
7.61
-13.45% 69.54%

Tarsus Pharmaceuticals Inc News

Latest updates
MarketBeat44 hours ago
Defense World02 Jun 202407:00 am
Seeking Alpha28 May 202407:00 am

Tarsus Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q1
Revenue111.2%27,614,00013,076,0001,871,0002,500,00010,000,000-15,277,0007,807,500338,0001,240,00022,017,00033,432,000
Costs and Expenses-65,298,000-42,806,00027,452,000-22,906,00020,501,00020,060,000-16,945,000--
Operating Expenses-------20,501,00020,060,00014,786,00016,945,00014,735,00022,718,000
  S&GA Expenses19.9%51,578,00043,005,00030,324,00015,096,00014,633,00011,994,00010,376,0007,946,0006,772,0006,671,0006,794,0005,160,000
  R&D Expenses-9.3%12,066,00013,305,00012,105,00012,356,00010,028,00010,912,0009,603,00012,081,0008,038,00010,209,0007,204,00016,261,000
EBITDA Margin39.2%-2.92-4.80-4.09-2.13-2.31-------
Interest Expenses-0.6%983,000989,000858,000684,000699,000633,000544,000316,000----
Income Taxes-------5,000-1,00054,000-341,00029,000313,000
EBT Margin39.1%-3.02-4.95-4.32-2.24-2.41-0.41-0.33-0.28-0.24---
Net Income14.7%-35,731,000-41,902,000-39,148,000-23,419,000-13,599,000-22,511,000-5,743,000-20,238,000-14,851,000-15,697,0006,345,00010,376,000
Net Income Margin33.6%-3.29-4.95-7.49-2.35-2.41-1.88-1.36-0.90-0.24---
Free Cashflow3.5%-37,963,000-39,335,000-32,737,000-22,310,000-11,001,000-18,707,000-4,381,000-15,447,000-12,395,0006,991,00020,535,000-
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32019Q4
Assets31.6%34926526818921122823625318117919020319417292.0058.00
  Current Assets33.0%34125625918320922523425017917618720119117189.0058.00
    Cash Equivalents-13.9%19422522710766.0072.0016924517517118417715616886.0058.00
  Inventory29.9%4.003.000.00-------------
  Net PPE-8.9%1.001.002.002.001.001.001.001.001.001.001.000.001.001.001.000.00
Liabilities8.1%74.0069.0055.0041.0038.0035.0034.0031.0032.0012.0011.0011.0011.006.007.001.00
  Current Liabilities15.1%43.0037.0023.0015.0013.0015.0014.0012.0013.0011.0010.0010.0010.005.006.001.00
  Long Term Debt0.4%30.0030.0030.0025.0025.0019.0019.0019.0019.00-------
    LT Debt, Non Current0.4%30.0030.0030.0025.0025.0019.0019.0019.0019.00-------
Shareholder's Equity39.7%275197214148173193203222149167179192183166--
  Retained Earnings-14.6%-280-244-202-163-132-108-95.16-72.70-66.91-46.67-31.82-16.10-22.50-32.84-21.40-6.03
  Additional Paid-In Capital25.8%5564424163113063022982942162132112092061994.000.00
Shares Outstanding10.3%38.0034.0033.0027.0027.0027.0024.0023.0021.0021.0021.0020.00----
Float----460---181---484----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q3
Cashflow From Operations3.9%-37,789-39,335-32,362-23,826-21,970-10,874-18,611-4,259-15,286-12,1217,11220,551-11,794-10,013-6,572-2,557-1,996--
  Share Based Compensation0.7%5,5195,4825,2505,1923,9063,6713,5833,5322,6742,1792,1192,7941,3634382241734.00--
Cashflow From Investing-672.7%-102,22417,85047,36864,09211,294-87,219-57,127-122-161-274-121-16.00-17550.00-135-335-36.00--
Cashflow From Financing450.5%108,77119,760104,8935105,013264-13674,73419,125-74.0075.001.0019.0091,76339,901134-27.00--
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

TARS Income Statement

2024-03-31
Condensed Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:  
Total revenues$ 27,614$ 2,500
Operating expenses:  
Research and development12,06612,356
Selling, general and administrative51,57815,096
Total operating expenses65,29827,452
Loss from operations before other income (expense)(37,684)(24,952)
Other income (expense):  
Interest income3,1172,293
Interest expense(983)(684)
Other income, net6056
Unrealized loss on equity investments(585)(65)
Change in fair value of equity warrants issued by licensee(201)(17)
Total other income, net1,9531,533
Net (loss) income(35,731)(23,419)
Other comprehensive loss:  
Unrealized (loss) gain on marketable securities and cash equivalents(61)4
Comprehensive loss$ (35,792)$ (23,415)
Earnings Per Share [Abstract]  
Net loss per share, basic (usd per share)$ (1.01)$ (0.88)
Net loss per share, diluted (usd per share)$ (1.01)$ (0.88)
Weighted Average Number of Shares Outstanding, Diluted [Abstract]  
Weighted-average shares outstanding, basic (shares)35,300,65526,742,023
Weighted-average shares outstanding, diluted (shares)35,300,65526,742,023
Product  
Revenues:  
Total revenues$ 24,720$ 0
Operating expenses:  
Cost of sales1,6540
License fees and Collaboration  
Revenues:  
Total revenues$ 2,894$ 2,500

TARS Balance Sheet

2024-03-31
Condensed Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 193,705$ 224,947
Marketable securities104,8192,495
Accounts receivable, net29,88516,621
Inventory4,0363,107
Other receivables1,4761,093
Prepaid expenses6,8037,868
Total current assets340,724256,131
Property and equipment, net1,3381,468
Intangible assets, net3,7673,867
Operating lease right-of-use assets2,1321,880
Long-term investments0631
Other assets1,3171,514
Total assets349,278265,491
Current liabilities:  
Accounts payable and other accrued liabilities36,57023,691
Accrued payroll and benefits5,95813,245
Total current liabilities42,52836,936
Term loan, net29,93329,819
Other long-term liabilities1,6061,748
Total liabilities74,06768,503
Commitments and contingencies (Note 7)
Stockholders’ equity:  
Preferred stock, $0.0001 par value; 10,000,000 authorized; no shares issued and outstanding00
Common stock, $0.0001 par value; 200,000,000 shares authorized; 37,749,468 shares issued and outstanding at March 31, 2024 (unaudited); 34,211,190 shares issued and outstanding at December 31, 202365
Additional paid-in capital555,655441,641
Accumulated other comprehensive loss(63)(2)
Accumulated deficit(280,387)(244,656)
Total stockholders’ equity275,211196,988
Total liabilities and stockholders’ equity$ 349,278$ 265,491
TARS
Tarsus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
 CEO
 WEBSITEtarsusrx.com
 INDUSTRYBiotechnology
 EMPLOYEES87

Tarsus Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Tarsus Pharmaceuticals Inc? What does TARS stand for in stocks?

TARS is the stock ticker symbol of Tarsus Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Tarsus Pharmaceuticals Inc (TARS)?

As of Thu Jun 13 2024, market cap of Tarsus Pharmaceuticals Inc is 1.25 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TARS stock?

You can check TARS's fair value in chart for subscribers.

What is the fair value of TARS stock?

You can check TARS's fair value in chart for subscribers. The fair value of Tarsus Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Tarsus Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TARS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Tarsus Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether TARS is over valued or under valued. Whether Tarsus Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Tarsus Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TARS.

What is Tarsus Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, TARS's PE ratio (Price to Earnings) is -8.45 and Price to Sales (PS) ratio is 27.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TARS PE ratio will change depending on the future growth rate expectations of investors.